Agenus to Present at the JMP Securities Healthcare Conference
June 19 2014 - 3:30PM
Business Wire
Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company
developing a portfolio of checkpoint modulators (CPMs), heat shock
protein vaccines and adjuvants, today announced that Robert Stein,
MD, PhD, the company’s Chief Scientific Officer, will present a
company overview at the JMP Securities Healthcare Conference at the
Westin Grand Central Hotel in New York City on Tuesday, June 24th
at 12:30 pm ET.
Web Cast Information
The live and archived webcast of the company presentation will
be accessible from the company’s website at
www.agenusbio.com/webcast. Please log in approximately 5-10 minutes
before each event to ensure a timely connection. The archived
replay will be available on the Agenus website for one month
following the conference.
About Agenus
Agenus is an immuno-oncology company developing a portfolio of
checkpoint modulators (CPMs), heat shock protein vaccines and
adjuvants. Agenus’ checkpoint modulator programs target GITR, OX40,
CTLA-4, LAG-3, TIM-3 and PD-1. The company’s proprietary discovery
engine Retrocyte Display® is used to generate fully human
therapeutic antibody drug candidates. The Retrocyte Display
platform uses a high-throughput approach incorporating IgG format
human antibody libraries expressed in mammalian B-lineage cells.
Agenus’ heat shock protein vaccines for cancer and infectious
disease are in Phase 2 studies. The company’s QS-21 Stimulon®
adjuvant platform is extensively partnered with GlaxoSmithKline and
Janssen and includes several candidates in Phase 3 trials. For more
information, please visit www.agenusbio.com, or connect with the
company on Facebook, LinkedIn, Twitter and Google+. For more
information, please visit www.agenusbio.com.
Forward-Looking Statement
This press release contains forward-looking statements,
including statements regarding the Company’s upcoming corporate
presentation. These forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially. These risks and uncertainties include, among others,
the factors described under the Risk Factors section of our
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission for the period ended March 31, 2014. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this document, and Agenus
undertakes no obligation to update or revise the statements. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement. Agenus’ business is subject
to substantial risks and uncertainties, including those identified
above. When evaluating Agenus’ business and securities, investors
should give careful consideration to these risks and
uncertainties.
Media and Investor Contact:Agenus Inc.Jonae R. Barnes,
617-818-2985Vice PresidentInvestor Relations andCorporate
Communicationsjonae.barnes@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Aug 2023 to Aug 2024